Tan Xiao-hua, Wu Bin, Liu Bing, Liu Xiu-li, Wang You-chen
Hematology Department, Beijing Military General Hospital, Beijing 100700, China.
Zhonghua Gan Zang Bing Za Zhi. 2008 Apr;16(4):289-93.
To investigate the effect of adenovirus vector encoding human vascular endothelial growth factor receptor-2 (hVEGFR-2 or hKDR) on breaking the immune tolerance and inducing immunity against murine hepatocellular carcinomas.
Human and mouse KDR cDNA were cloned from human umbilical vein endothelial cells (HUVEC) and C57BL/6 mouse embryo cells respectively using RT-PCR, and then Ad hKDR and Ad mKDR were constructed. Seven days after immunization of the mice with Ad hKDR or Ad mKDR, an analysis of cytotoxic activity of antigen-specific cytotoxic T lymphocytes (CTL) was made by lactate dehydrogenase (LDH) release assay, in which splenocytes of the immunized mice acted as effectors and Hepa 1-6/mKDR cells as the targets. In addition, the survival of the mice immunized with Hepa 1-6 hepatoma cells was checked.
Seven days after immunization, the 6 h killing activities of CTL elicited by the Ad hKDR were 84.3%+/-6.7%, 71.5%+/-5.2%, and 44.6%+/-4.7% at the ratio of the effectors:targets (E:T) of 100:1, 50:1, and 25:1, respectively. Correspondingly, the CTL activities by Ad mKDR were 65.2%+/-6.1%, 46.7%+/-5.0%, and 22.6%+/-3.7%. Sixty percent of the Ad hKDR-immunized mice with 510(6) Hepa 1-6 hepatoma cells were still alive two months after the inoculation, whereas just 40% of the Ad mKDR-immunized mice with 210(6) Hepa 1-6 cells survived two months. When CD8+ or CD4+ T lymphocytes were deleted in the mice the above mentioned CTL activities and protection of the mice from tumors disappeared.
Adenovirus vector-mediated xenogeneic KDR can effectively break the immune tolerance to hepatocellular carcinomas in an animal model and induce a strong antigen-specific T cell response, which is dependent on CD8+ and CD4+ T cells.
研究编码人血管内皮生长因子受体-2(hVEGFR-2或hKDR)的腺病毒载体对打破免疫耐受及诱导抗小鼠肝细胞癌免疫的作用。
分别采用逆转录聚合酶链反应(RT-PCR)从人脐静脉内皮细胞(HUVEC)和C57BL/6小鼠胚胎细胞中克隆人及小鼠KDR cDNA,然后构建Ad hKDR和Ad mKDR。用Ad hKDR或Ad mKDR免疫小鼠7天后,通过乳酸脱氢酶(LDH)释放试验分析抗原特异性细胞毒性T淋巴细胞(CTL)的细胞毒活性,其中免疫小鼠的脾细胞作为效应细胞,Hepa 1-6/mKDR细胞作为靶细胞。此外,检查用Hepa 1-6肝癌细胞免疫的小鼠的存活情况。
免疫7天后,在效应细胞与靶细胞比例(E:T)为100:1、50:1和25:1时,Ad hKDR诱导的CTL的6小时杀伤活性分别为84.3%±6.7%、71.5%±5.2%和44.6%±4.7%。相应地,Ad mKDR诱导的CTL活性分别为65.2%±6.1%、4�.7%±5.0%和22.6%±3.7%。接种5×10⁶个Hepa 1-6肝癌细胞的Ad hKDR免疫小鼠中有60%在接种后两个月仍存活,而接种2×10⁶个Hepa 1-6细胞的Ad mKDR免疫小鼠中只有40%存活两个月。当小鼠体内的CD8⁺或CD4⁺T淋巴细胞被清除时,上述CTL活性及小鼠对肿瘤的保护作用消失。
腺病毒载体介导的异种KDR能在动物模型中有效打破对肝细胞癌的免疫耐受并诱导强烈的抗原特异性T细胞反应,这依赖于CD8⁺和CD4⁺T细胞。